Generate Biomedicines Inc (GENB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Cash Flows From Operating Activities | ||
| Net Income | -222,965 | -181,384 |
| Depreciation Amortization | 10,395 | 9,901 |
| Accounts receivable | 308 | -213 |
| Accounts payable and accrued liabilities | -2,130 | 3,499 |
| Other Working Capital | -14,616 | 28,118 |
| Other Operating Activity | 28,389 | 22,329 |
| Operating Cash Flow | $-200,619 | $-117,750 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -3,514 | -3,437 |
| Purchase Of Investment | -164,731 | -282,979 |
| Sale Of Investment | 285,012 | 228,691 |
| Investing Cash Flow | $116,767 | $-57,725 |
| Cash Flows From Financing Activities | ||
| Debt Repayment | -8,161 | -11,124 |
| Common Stock Issued | 23,070 | 97,451 |
| Other Financing Activity | 13,150 | 5,000 |
| Financing Cash Flow | $28,059 | $91,327 |
| Beginning Cash Position | 181,831 | 265,979 |
| End Cash Position | 126,038 | 181,831 |
| Net Cash Flow | $-55,793 | $-84,148 |
| Free Cash Flow | ||
| Operating Cash Flow | -200,619 | -117,750 |
| Capital Expenditure | -3,514 | -3,447 |
| Free Cash Flow | -204,133 | -121,197 |